Mayinglong Pharmaceutical Group (600993.SH) announced that the company recently received the approval and issuance of the National Medical Products Administration...
According to the Zhītōng finance and economics APP, Mayinglong Pharmaceutical Group (600993.SH) announced that the company recently received the approval and issuance of the National Medical Products Administration's "Drug Clinical Trial Approval Notice" (Notification number: 2024LP02795, 2024LP02796, 2024LP02797, 2024LP02798), and will conduct clinical trials in the near future.
MYL ointment (Musk Hemorrhoid and Pain Relief Ointment, provisional) is a traditional Chinese medicine compound preparation, mainly used for clearing heat and dampness, reducing swelling, relieving pain, stopping bleeding, and promoting tissue regeneration. Indications include improving symptoms of hemorrhoids such as bleeding, pain, prolapse, as well as post-hemorrhoid surgery pain, swelling, promoting wound healing. Compared with similar products, MYL ointment (Musk Hemorrhoid and Pain Relief Ointment, provisional) has a wider range of use in improving hemorrhoid symptoms, and can also be used to improve post-hemorrhoid surgery complications, promoting wound healing. MYL ointment (Musk Hemorrhoid and Pain Relief Ointment, provisional) was independently developed by the company, with a cumulative research and development investment of 13.5855 million yuan as of the announcement date.
